^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Hepatocellular Cancer
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    AstraZeneca Press Release
    Title:

    Imfinzi plus Imjudo approved in Japan for advanced liver and non-small cell lung cancers, and Imfinzi approved for unresectable biliary tract and liver cancers

    Published date:
    12/28/2022
    Excerpt:
    AstraZeneca’s immunotherapies Imfinzi (durvalumab) and Imjudo (tremelimumab) have been approved in Japan for the treatment of three cancer types: advanced liver, biliary tract and lung….The approvals authorise Imfinzi in combination with Imjudo for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC) and for the treatment of adult patients with unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) in combination with chemotherapy. Imfinzi was also authorised for the treatment of adult patients with unresectable HCC as monotherapy and for the treatment of adult patients with curatively unresectable biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    03/29/2022
    Excerpt:
    Hepatocellular Carcinoma...Other Recommended Regimens...Durvalumab added as a Category 2A recommendation